In its pharmaceutical division, Bayer continued to suffer from generic competition to Xarelto, with sales of the blockbuster blood thinner slumping by 40% in the quarter, as well as eye medicine Eylea. The company is counting on growth from cancer drug Nubeqa and kidney therapy Kerendia, as well as new launches, to return the unit to growth by 2027.






